Fabrice Lucien, PhD

🇫🇷🇨🇦🇺🇸 Associate Professor of Urology & Immunology - Mayo Clinic - Basic and Translational Research - Liquid biopsies and next-gen cancer immunotherapies

[Gianrico Farrugia @GFarrugiaMD]

I’m pleased to share Mayo Clinic has announced a strategic collaboration with @Microsoft to develop and deploy a frontier AI model designed specifically for healthcare. Read more: https://t.co/I6RGCtR8MF

[Zach Klaassen @zklaassen_md]

Brilliant discussant slide from @CalaisJeremie putting into context the results from AcTION and CONV01-alpha with PSMAddition and VISION

@urotoday #ASCO26

[Fabrice Lucien, PhD @flscientist]

@bashier_roya @AJangMD @MayoCancerCare @MayoUrology Yes we do :)

[Fabrice Lucien, PhD @flscientist]

Exciting work on EV-based biomarkers in advanced prostate cancer treated with Lu-177 PSMA, spearheaded by @AJangMD @MayoCancerCare @MayoUrology

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Ab#5068 @ASCO #ASCO26 by @AJangMD👉 https://t.co/9FpEfmhiIJ👉Plasma-derived extracellular vesicles (EVs) in 123 pts w/ mPC treated w/ Lu-177 #prostatecancer➡️CEACAM5 + TROP2 EV composite best predicted PSA50 response (OR 2.96)👇 @flscientist @oncoalert @urotoday @PCF_science

[Mayo Clinic Urology @MayoUrology]

Mayo Clinic Urology was honored to host visiting professor Dr. Hashim Ahmed for a discussion on advances in prostate cancer screening, precision diagnosis, and focal therapy.
#ProstateCancer #FocalTherapy @imperialcollege @LondonProstate1 @SBoorjian @DerekLomas

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

Biochemical Recurrence Irradiation or Observation (BRIO) in patients with prostate cancer: protocol for a randomised control trial (Study Protocol)

https://t.co/itjQDJ7ckH

BRIO is a prospective randomized trial evaluating whether immediate salvage radiotherapy (SRT) ☢️ improves outcomes versus observation with delayed image-guided treatment in men with biochemical recurrence after radical prostatectomy who have negative mpMRI and PSMA-PET/CT imaging.

The study will enroll 312 patients with PSA 🧪 0.2–1.5 ng/mL and assess distant recurrence-free survival, quality of life, adverse effects, and biomarker development to clarify optimal management of imaging-negative recurrent #ProstateCancer after surgery overall

@DrStish @JakeOrmeMDPhD @vidit_sharma_ @JackAndrewsMD @flscientist

@OncoAlert 🚨
@Silke_Gillessen
@AOmlin
@weoncologists

[Aadel Chaudhuri, MD PhD @aadel_chaudhuri]

What a day it has been!!!

@AaronNewmanLab and I started this journey years ago back when we were both junior faculty. A difficult question — Can we perform liquid biopsy of the tumor microenvironment?

Spoiler alert. We finally did it! In @Nature & on @CNN today w/ @jaketapper!!

[Fabrice Lucien, PhD @flscientist]

Meet the Locals at #ISEV2026 - learning about the EV research done in Puerto Rico

[Fabrice Lucien, PhD @flscientist]

Dr. Olivier De Jong from Utrecht University with an outstanding talk on EV engineering to allow gene editing in recipient cells. #ISEV2026

[Fabrice Lucien, PhD @flscientist]

Our talented collaborator Dr. Ishwor Thapa, bioinformatician and data scientist at UNO, presenting an important comparative analysis of total and small RNAseq for EV biomarker discovery.
#ISEV2026

[Fabrice Lucien, PhD @flscientist]

Dr. Marca Wauben takes the stage to talk about the relationship between EV cargo and function. #ISEV2026

[Fabrice Lucien, PhD @flscientist]

Dr. Rubia Noori, postdoc in our lab, chairing the session on Diagnostics/Prognostics biomarkers #ISEV2026

[Fabrice Lucien, PhD @flscientist]

Opening ceremony of #ISEV2026 annual meeting!

[Fabrice Lucien, PhD @flscientist]

Uta Erdbruegger presenting the current status of EV-based biomarkers and translational challenges #ISEV2026

[Fabrice Lucien, PhD @flscientist]

@doldivizio educating the scientific community on the extracellular vesicle terminology #ISEV2026

[Fabrice Lucien, PhD @flscientist]

Kicking of #ISEV2026 in San Juan (PR) with the Education Day. Great way to get up to speed on the fundamentals of extracellular vesicles (EVs).

[Mayo Clinic Urology @MayoUrology]

We were honored to host Dr. Michael Blute today for a lecture on surgical management of tumor thrombus in RCC.

Key insights on operative strategy and multidisciplinary care underscored opportunities to improve outcomes in complex cases.

[NEJM @NEJM]

In cisplatin-ineligible patients with muscle-invasive bladder cancer, enfortumab vedotin–pembrolizumab plus surgery led to better event-free survival (74.7%, vs. 39.4%) and overall survival (79.7%, vs. 63.1%) than surgery alone at 2 years. Full phase 3 KEYNOTE-905 trial results and Research Summary: https://t.co/bzVbmJXHMD

[UroToday.com @urotoday]

Long-term marrow toxicity: Rates and risk factors. Presentation by Daniel Childs, MD @MayoClinic. #PSMA26 written coverage by @zklaassen_md @GACancerCenter > https://t.co/eqYenD4Ku7 @PSMAconference #2026PSMAandBeyond